You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

 

Online download statistics by month:

Online download statistics by month: July 2021 to September 2025

AbstractFullPdf
Jul 2021613613128
Aug 2021989989262
Sep 2021228228651
Oct 202123623691
Nov 202122021976
Dec 202114814751
Jan 2022263273134
Feb 2022828480
Mar 202216817557
Apr 202210110552
May 202212913282
Jun 202213013968
Jul 202215216071
Aug 202214314865
Sep 202213714044
Oct 202213013469
Nov 20229910049
Dec 2022676735
Jan 2023929232
Feb 2023999934
Mar 2023899062
Apr 2023595942
May 2023545733
Jun 2023606131
Jul 2023606040
Aug 2023474723
Sep 2023394023
Oct 2023696937
Nov 2023818330
Dec 202311911926
Jan 20245657131
Feb 2024434626
Mar 2024555565
Apr 2024575736
May 2024575725
Jun 2024696841
Jul 2024646520
Aug 2024353421
Sep 2024434418
Oct 2024464629
Nov 2024424332
Dec 2024858636
Jan 2025585937
Feb 2025707144
Mar 2025606029
Apr 202511211373
May 2025555739
Jun 2025425133
Jul 2025220
Sep 2025110
Total595560373213